drug

Oxytocin nasal spray

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Central Institute of Mental Health, Mannheim
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment
NCT06881810Phase 2Recruiting
Target Engagement and Response to Oxytocin
NCT03245437Phase 4Completed
Oxytocin and Social Decision Making in Schizophrenia
NCT04176835—Completed

KOLs & investigators

2
Stephen R. Marder, MDKOL score 14
Dusan Hirjak, Prof. Dr.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Central Institute of Mental Health, Mannheim
company
trial
Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on to Psychosocial Treatment
PHASE2
trial
Target Engagement and Response to Oxytocin
PHASE4
trial
Oxytocin and Social Decision Making in Schizophrenia
NA
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Schizophrenia Spectrum Disorders (SSD)
indication
KOL
Stephen R. Marder, MD
KOL score 14
person
Dusan Hirjak, Prof. Dr.
KOL score —
person